Aislinn Antrim, Managing Editor

An 11-fold increase in geometric mean neutralizing antibody titers was reported at 2 weeks after the second booster compared to 5 months after the first booster dose.

Patients in the atogepant 60 mg daily and 30 mg twice daily treatment arms of the study experienced a decrease of 6.88 and 7.46 monthly migraine days, respectively.

Growing evidence indicates that PARP inhibition, both as frontline maintenance and recurrent maintenance, is important for many patients with ovarian cancer.

The death rate from cervical cancer has dropped by more than 50% since 1975.

Use of mirvetuximab soravtansine monotherapy in patients with ovarian cancer resulted in meaningful anti-tumor activity, consistent safety, and favorable tolerability.

Hormone replacement therapy can improve quality of life without necessarily increasing the risk of recurrence.

Speakers at the annual Society of Gynecologic Oncology annual meeting emphasized the theme of building bridges and breaking barriers to advance gynecologic care.

Despite early excitement about the potential for pharmacists to prescribe COVID-19 oral antivirals, the program does not provide that ability.

Researchers found that in a program of biennial screening of women aged 50 to 74 years, approximately 1 in 7 screen-detected breast cancer cases would be overdiagnosed.

The proof-of-concept study is expected to announce topline safety, tolerability, and immunogenicity results by the end of 2022.

Durvalumab plus chemotherapy did not increase the discontinuation rate due to adverse events compared to chemotherapy alone.

Durable responses mark a significant advancement over chemotherapy, which may have only been effective for 9 to 10 months.

Study findings support the role of tezepelumab-ekko as a first-in-class treatment for a broad population of patients living with severe asthma, irrespective of biomarker levels.

Filgrastim-ayow is indicated for the treatment of neutropenia, which is commonly experienced by patients receiving chemotherapy.

A supplemental application was also submitted for an oral suspension formulation to provide an alternative administration option for children.

Any patients aged 60 years or older who does not meet risk-based recommendations can still receive hepatitis B vaccination.

PDS founder and executive chairman Dan Benamoz, RPh, discussed a few of the most exciting speakers and opportunities happening during the conference.

One out of every 4 pharmacists in Georgia said emergency contraception was not available at the store and ended the call.

Data suggest that omicron-specific CD8-positive T cell responses were more than 80% cross-reactive with the CD8-positive T cell response to the original strain of the virus.

Applying these findings in practice could improve clinicians’ ability to offer truly personalized cancer therapy by enabling consideration of toxicity along with other data predicting patients’ responses.

A product containing phosphoric acid as well as alcohol successfully neutralized all of the virus particles.

Selinexor demonstrated a 37% increase in probability that patients treated with the drug will be in remission at 12 months.

The majority of study participants demonstrated improvement of infraorbital hollows through 1 year.

Communication, flexibility, and virtual solutions will remain key as the COVID-19 pandemic continues.

Trametinib emerged as a novel therapeutic approach for low-grade serous carcinoma due to a high prevalence of activating mutations in the mitogen-activated protein kinase signaling pathway.

Patients receiving brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in the frontline setting had a 41% reduction in the risk of death.

Being fully vaccinated was associated with a lower risk of requiring supplemental oxygen compared to being unvaccinated, as well as a lower risk of intensive care unit admission.

Children ages 5 to under 12 years received a 2-dose schedule of 10 µg each whereas children under age 5 received a lower 3 µg dose for each injection in the phase 2/3 study.

The novel CAR T cells can deliver a toxic drug payload directly to a tumor, killing tumor cells that contain the cancer marker and nearby cancer cells that do not.

In a clinical trial, the median annualized bleeding rates for all bleeds was reduced from a historical median of 5 to an on-study median of 2.3, which is a 54.7% reduction.